Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

High number of Omicron mutations render antibodies ineffective – study

The highly contagious COVID-19 Omicron variant has a large number of uniquely specific mutations that allow it to evade pre-existing antibodies in the human body, accounting for its high rate of infection, new research carried out by the University of Minnesota has found.

The peer-reviewed study titled “Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies” was first published in the Journal of Autoimmunity and was produced by Kamlendra Singh, a professor in the University of Missouri College of Veterinary Medicine and assistant director of the college’s Molecular Interactions Core and Bond Life Sciences Center investigator.

The research team set out to gather data on the mutations found in the spike protein (S-protein) of the Omicron variant. An S-protein refers to a large structure projecting from the surface of the virus’s outermost layer, and they are most commonly associated with all forms of coronavirus cells.

Source: The Jerusalem Post

https://www.jpost.com/health-and-wellness/coronavirus/article-694237

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!